Clarity Pharmaceuticals

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Clarity Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials 3 currently recruiting 2 completed early-phase tilt upper quartile by trial count

Clarity Pharmaceuticals: 7 sponsored US clinical trials, 3 recruiting.

Clarity Pharmaceuticals sponsors 7 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 2 completed. 2 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 2 trials.

Upper-quartile sponsor footprint

Clarity Pharmaceuticals sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Open and recent trials

7 total, page 1 of 1

RECRUITING Phase 3

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

NCT06970847
RECRUITING Phase 3

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

NCT06056830
RECRUITING Phase 1

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)

NCT04868604
TERMINATED Phase 1

64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)

NCT05633160
COMPLETED Phase 2

64Cu-SAR-BBN for Identification of Participants With Recurrence of Prostate Cancer (SABRE)

NCT05407311
COMPLETED Phase 1

64Cu-SAR-bisPSMA for Identification of Participants With Recurrence of Prostate Cancer (COBRA)

NCT05249127
TERMINATED Phase 1

67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma

NCT04023331

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 1
Phase 3 2

Therapeutic Areas

Prostate Cancer 2
Cryotherapy 1
Prostate Cancer Patients Treated by Radiotherapy 1
Prostate Cancer Patients Who Have Brachytherapy Seed Implant 1
Prostate Cancer Recurrent 1
Prostate Cancer Patients With Detectable PSA Following Prostatectomy 1
Prostatic Neoplasms, Castration-Resistant 1
Prostatic Neoplasms 1

What is open in the Clarity Pharmaceuticals pipeline

3 recruiting of 7 indexed (43% open); 2 completed (29%).

Phase mix: 2 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Prostate Cancer (2 trials), 7 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Clarity Pharmaceuticals: open-pipeline peers nationwide

Peers matched on 7 registered trials and 43% open enrollment, not the therapeutic-area sidebar.

Clarity Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 6.97.07.077.07.07.1 0%10%20%30%40%50% Total trials Recruiting share Clarity Pharmaceuticals3M4Life Research89bioAbbott Diagnostics DivisionAlphatec SpineColorado Center for Reproductive MedicineDavid MossEyeBiotech
Clarity Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Clarity Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 trials (± recruiting share)

Sponsors near 43% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Clarity Pharmaceuticals page

7 registered trials is a research-attention snapshot, not an endorsement of Clarity Pharmaceuticals or any single study.

  • 3 of Clarity Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Prostate Cancer is the condition Clarity Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Clarity Pharmaceuticals pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.